The importance of this pathway has been well established in thyroid cancer [11,12], where in PTCs the MAPK pathway is driven by the activation of point mutations of the BRAF and RAS genes and in the RET/PTC rearrangement, these genetic alterations being found in more than 70% of PTCs [13]. The gene discussed is RET; the disease is thyroid gland carcinoma.